MarketCap
Facebook
X
TelegramQuarterly report 2025-Q4
added 05-06-2026
Kamada Ltd. Market Cap 2011-2026 | KMDA
As of May 15, 2026 Kamada Ltd. has a market cap of $ 455 M
Capitalization is the market value of a company whose shares are traded on the stock exchange. It is calculated by multiplying the market price of a share by the total number of the company's shares. Capitalization indicates volatility, risk, and growth potential. This metric is often used for a quick assessment of a company’s investment profile.[1]
Capitalization is an important indicator for investors and analysts, as it helps determine the size and significance of a company in the stock market. Companies with large capitalization are considered more stable and reliable, as they have more resources and financial power to grow and survive in the market.
This metric can be divided into several categories: small (from 300 million to 2 billion dollars), medium (from 2 to 10 billion dollars), and large (over 10 billion dollars). Companies with different levels of capitalization have their own characteristics and risks, so investors usually take this indicator into account when making investment decisions.
Capitalization can also change over time depending on the share price and the number of shares in circulation. Therefore, it is a dynamic indicator that requires constant monitoring and analysis to make well-informed investment decisions.
Annual Market Cap Kamada Ltd.
| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 490 M | 413 M | 298 M | 260 M | 271 M | 284 M | 264 M | 212 M | 207 M | 222 M | 134 M | 145 M | 495 M | - | - |
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| 495 M | 134 M | 284 M |
References
- Pavone, P. (2019). Market capitalization and financial variables: Evidence from Italian listed companies. International Journal of Academic Research Business and Social Sciences, 9(3), 1356-1371.
Market Cap of other stocks in the Biotechnology industry
| Issuer | Market Cap | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
 |
FSD Pharma
HUGE
|
50.7 M | - | 5743.5 % | $ 69.7 M |  Canada |
 |
MorphoSys AG
MOR
|
315 M | - | 2.43 % | $ 254 M |  Germany |
 |
Happiness Biotech Group Limited
HAPP
|
8.91 M | - | 1.35 % | $ 17.8 M |  China |
 |
Amphastar Pharmaceuticals
AMPH
|
1.25 B | $ 16.88 | -2.43 % | $ 789 M |  USA |
 |
AgeX Therapeutics
AGE
|
29.1 M | - | -10.17 % | $ 12.2 K | USA |
 |
Compugen Ltd.
CGEN
|
196 M | $ 2.79 | -8.09 % | $ 261 M |  Israel |
 |
Coherus BioSciences
CHRS
|
226 M | $ 1.6 | -2.15 % | $ 187 M | USA |
 |
I-Mab
IMAB
|
127 M | - | - | $ 866 M | China |
 |
Alexion Pharmaceuticals, Inc.
ALXN
|
33.6 B | - | - | $ 40.3 B | USA |
 |
Biophytis SA
BPTS
|
549 M | - | -13.47 % | $ 169 M |  France |
 |
Genfit SA
GNFT
|
168 B | - | 2.54 % | $ 160 B | France |
 |
AstraZeneca PLC
AZN
|
115 B | - | - | $ 96.9 B |  Britain |
 |
EyeGate Pharmaceuticals, Inc.
EYEG
|
28.9 M | - | -1.52 % | $ 24.7 M | USA |
 |
Arcturus Therapeutics Holdings
ARCT
|
217 M | $ 7.56 | -3.45 % | $ 207 M | Israel |
 |
Athira Pharma
ATHA
|
1.62 M | - | - | $ 269 M | USA |
 |
BiondVax Pharmaceuticals Ltd.
BVXV
|
740 M | - | 0.74 % | $ 768 M | Israel |
 |
Galera Therapeutics
GRTX
|
7.65 M | - | -32.59 % | $ 7.61 M | USA |
 |
Esperion Therapeutics
ESPR
|
561 M | $ 3.13 | 0.32 % | $ 651 M | USA |
 |
Exelixis
EXEL
|
11.7 B | $ 50.41 | -1.36 % | $ 13.7 B | USA |
 |
Fortress Biotech
FBIO
|
77.8 M | $ 2.43 | 5.65 % | $ 67.8 M | USA |
 |
Midatech Pharma plc
MTP
|
1.44 B | - | -18.52 % | $ 27.3 M | Britain |
|
Forte Biosciences
FBRX
|
335 M | $ 23.1 | -3.57 % | $ 299 M | USA |
 |
Fennec Pharmaceuticals
FENC
|
169 M | $ 9.76 | 5.63 % | $ 279 M | USA |
 |
AbCellera Biologics
ABCL
|
962 M | $ 4.09 | -7.05 % | $ 1.22 B | Canada |
 |
Autolus Therapeutics plc
AUTL
|
322 M | $ 1.59 | - | $ 423 M | Britain |
 |
Институт стволовых клеток человека
ISKJ
|
2.83 B | - | - | - |  Russia |
 |
BioNTech SE
BNTX
|
22 B | $ 89.16 | -3.08 % | $ 21.5 B | Germany |
 |
Checkmate Pharmaceuticals
CMPI
|
52.7 M | - | - | $ 231 M | USA |
 |
Galectin Therapeutics
GALT
|
178 M | $ 2.22 | -5.74 % | $ 142 M | USA |
 |
Gilead Sciences
GILD
|
183 B | $ 130.07 | -1.51 % | $ 162 B | USA |
 |
Genmab A/S
GMAB
|
1.41 B | $ 26.8 | -0.37 % | $ 1.73 B |  Danmark |
 |
Advaxis
ADXS
|
1.87 M | - | -9.65 % | $ 45.9 M | USA |
 |
Can-Fite BioPharma Ltd.
CANF
|
4.81 M | $ 3.41 | -2.25 % | $ 5.61 M | Israel |
 |
Aeterna Zentaris
AEZS
|
14.8 M | - | 5.93 % | $ 314 M | Canada |
 |
Aeglea BioTherapeutics
AGLE
|
724 M | - | - | $ 1.01 B | USA |
 |
CureVac N.V.
CVAC
|
3.53 B | - | - | $ 867 M | Germany |
 |
Applied Genetic Technologies Corporation
AGTC
|
32.8 M | - | - | $ 26.5 M | USA |
 |
Grifols, S.A.
GRFS
|
4.52 B | $ 7.74 | -0.64 % | $ 5.26 B |  Spain |
 |
AIkido Pharma
AIKI
|
19.6 M | - | 1.93 % | $ 17.4 M | USA |
|
Enlivex Therapeutics Ltd.
ENLV
|
43.9 M | $ 0.72 | -1.05 % | $ 32.9 M | Israel |
 |
Akero Therapeutics
AKRO
|
3.25 B | - | - | $ 3.67 B | USA |
 |
Eton Pharmaceuticals
ETON
|
559 M | $ 29.69 | -0.92 % | $ 799 M | USA |
 |
Aptose Biosciences
APTO
|
2.32 M | - | -45.71 % | $ 1.2 M | Canada |
 |
Aptinyx
APTX
|
9.48 M | - | -39.0 % | $ 4.57 M | USA |
 |
Akouos
AKUS
|
172 M | - | 0.23 % | $ 488 M | USA |
 |
Albireo Pharma
ALBO
|
538 M | - | -0.23 % | $ 916 M | USA |
 |
AlloVir
ALVR
|
13.1 M | - | 4.14 % | $ 49.1 M | USA |
 |
Allakos
ALLK
|
114 M | - | - | $ 28.6 M | USA |
 |
Arcutis Biotherapeutics
ARQT
|
3.44 B | $ 21.51 | -0.3 % | $ 2.74 B | USA |
 |
Allena Pharmaceuticals
ALNA
|
71.4 M | - | 3.16 % | $ 1.9 M | USA |